Photo

Photo detail

Stories this photo appears in:

Halozyme Therapeutics, Janssen Biotech Sign Agreement

Halozyme Therapeutics Inc., a San Diego-based biopharmaceutical company, will receive $15 million as an initial payment from Pennsylvania-based Janssen Biotech Inc. as part of a collaboration and license agreement to develop and commercialize products combining Halozyme’s technology with Janssen’s compounds.

Tease photo